Padraig Dixon1, Charlotte Chamberlain2, William Hollingworth2. 1. School of Social and Community Medicine, University of Bristol, Bristol, UK. Electronic address: padraig.dixon@bristol.ac.uk. 2. School of Social and Community Medicine, University of Bristol, Bristol, UK.
Abstract
BACKGROUND: The Cancer Drugs Fund (CDF) will have spent more than £1 billion between October 2010 and the introduction of reforms to its structure and operations in July 2016. There has been much more debate about the existence of the fund than about how it spent its substantial budget. It is important to undertake a retrospective examination of "where the money went" in light of the substantial reforms that will be introduced in 2016. OBJECTIVES: We review the means by which the CDF made recent funding decisions for cancer drugs to provide an assessment of the merits of the CDF "model" as a basis for allocation decisions. We assess the extent to which proposed reforms could overcome defects in the original CDF model of prioritization, and lessons for other countries. METHODS: We provide a narrative commentary on CDF's methods and processes since 2014. We evaluate methods against best practice in cost-effectiveness analysis, and processes against the "accountability for reasonableness" framework. We comment on reforms to the fund. RESULTS: There are no grounds for concluding that the opportunity costs imposed on cancer patients were well evidenced, or the product of legitimate deliberative processes. We note that some of these issues will be addressed in the next incarnation of the fund, but the rationale for the fund's existence remains unconvincing. CONCLUSIONS: It is important and timely to debate how cancer drugs appraisal ought to be conducted to confront the consequences of CDF's model of appraisal. We conclude that it did matter that the CDF was not NICE.
BACKGROUND: The Cancer Drugs Fund (CDF) will have spent more than £1 billion between October 2010 and the introduction of reforms to its structure and operations in July 2016. There has been much more debate about the existence of the fund than about how it spent its substantial budget. It is important to undertake a retrospective examination of "where the money went" in light of the substantial reforms that will be introduced in 2016. OBJECTIVES: We review the means by which the CDF made recent funding decisions for cancer drugs to provide an assessment of the merits of the CDF "model" as a basis for allocation decisions. We assess the extent to which proposed reforms could overcome defects in the original CDF model of prioritization, and lessons for other countries. METHODS: We provide a narrative commentary on CDF's methods and processes since 2014. We evaluate methods against best practice in cost-effectiveness analysis, and processes against the "accountability for reasonableness" framework. We comment on reforms to the fund. RESULTS: There are no grounds for concluding that the opportunity costs imposed on cancerpatients were well evidenced, or the product of legitimate deliberative processes. We note that some of these issues will be addressed in the next incarnation of the fund, but the rationale for the fund's existence remains unconvincing. CONCLUSIONS: It is important and timely to debate how cancer drugs appraisal ought to be conducted to confront the consequences of CDF's model of appraisal. We conclude that it did matter that the CDF was not NICE.
Authors: Liz Morrell; Sarah Wordsworth; Anna Schuh; Mark R Middleton; Sian Rees; Richard W Barker Journal: BMC Health Serv Res Date: 2018-05-31 Impact factor: 2.655
Authors: Seung-Lai Yoo; Dae-Jung Kim; Seung-Mi Lee; Won-Gu Kang; Sang-Yoon Kim; Jong Hyuk Lee; Dong-Churl Suh Journal: Int J Environ Res Public Health Date: 2019-01-21 Impact factor: 3.390